ARTICLE | Company News
ICER to review peanut allergy therapies from Aimmune, DBV
November 20, 2018 11:46 PM UTC
The Institute for Clinical and Economic Review (ICER) will review peanut allergy therapies AR101 from Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Viaskin Peanut from DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). ICER announced the review in a scoping document Tuesday. The institute's California Technology Assessment Forum (CTAF) will meet to discuss the products on June 11, 2019.
ICER will assess the cost-effectiveness of the therapies to treat children ages 4-17 with peanut allergy. The review will take into consideration both the child and caregivers' quality of life (QOL), as well as treatment-related serious adverse events...